Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: David Mrazek, Brian Athey, Tracy Glauser, James Kennedy, and more


AssureRx Health, a neuropsychiatric personalized medicine company, has formed a scientific advisory board, which will guide the company's R&D efforts on pharmacogenomic products.

The advisory board members include:David Mrazek, pediatrics and psychiatry professor at the Mayo Clinic; Brian Athey, associate director of the Michigan Institute for Clinical Health Research; Tracy Glauser, associate director of clinical, translational, outcomes and health services research at the Cincinnati Children's Research Foundation; James Kennedy, director of neuroscience research at the Tanenbaum Center for Pharmacogenetics, University of Toronto; Lawrence Lesko, director of the Center for Pharmacometrics and Systems Pharmacology, University of Florida College of Pharmacy; John Pestian, professor of pediatrics and computer science at the University of Cincinnati; Sheldon Preskorn, professor in the psychiatry and behavioral science department at the University of Kansas School of Medicine; and Wolfgang Sadee, chair of the department of pharmacology at the Ohio State University School of Medicine.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.